Novavax's coronavirus vaccine, Nuvaxovid, has earned approval or authorization in dozens of countries worldwide. Thanks to sales related to this product, the biotech's latest financial update looked pretty good on the surface. For fiscal 2022, Novavax reported total revenue of $1.9 billion, almost 73% higher than in the previous year.